Valion Bio (VIBO) AGM 2026 summary

Opening remarks and agenda

• Meeting opened by CEO, marking the first annual meeting under the new company name and Nasdaq ticker VBIO.

• Emphasis on shareholder engagement as foundational to value creation.

• Introduction of board members and key executives in attendance.

• Meeting procedures, voting eligibility, and quorum established.

Financial performance review

• Over $140 million invested in lead drug development, with more than 300 patients dosed.

• 2025 described as a year of fundamental transformation, with 2026 focused on execution.

Board and executive committee updates

• Dean Zikria nominated and elected as Class 2 Director for a three-year term.